|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.88 USD | -0.29% |
|
-2.36% | -16.19% |
| 11/05 | Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing | MT |
| 04/05 | CSL, Resmed, Cochlear Lead Losses on ASX | MT |
Business description: ResMed, Inc.
- medical devices (51.8%);
- masks (35.7%);
- software as a service (12.5%): residential care management software solutions.
At the end of June 2025, the group had 8 production sites located in the United States (3), Australia, China, Singapore, Malaysia and France.
The United States accounts for 63.8% of net sales.
Number of employees: 10,600
Sales by Activity: ResMed, Inc.
| Fiscal Period: June | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Sleep and Breathing Health | 282.32Cr | 317.73Cr | 372.5Cr | 410.12Cr | 450.49Cr |
Residential Care Software | 37Cr | 40Cr | 50Cr | 58Cr | 64Cr |
Geographical breakdown of sales: ResMed, Inc.
| Fiscal Period: June | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 196.27Cr | 224.94Cr | 271.99Cr | 298.01Cr | 328.56Cr |
Rest of The World | 123.41Cr | 132.87Cr | 150.31Cr | 170.52Cr | 186.07Cr |
Executive Committee: ResMed, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 53 | 01/03/2013 |
Aaron Bloomer
DFI | Director of Finance/CFO | 40 | 04/05/2026 |
Jim Ellis
CMP | Compliance Officer | - | 01/01/2018 |
| Chief Tech/Sci/R&D Officer | - | 01/02/2024 | |
Carlos Nunez
CTO | Chief Tech/Sci/R&D Officer | - | 03/01/2017 |
Composition of the Board of Directors: ResMed, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Ron Taylor
BRD | Director/Board Member | 78 | 01/01/2005 |
Mick Farrell
CHM | Chairman | 53 | 25/01/2023 |
Peter Farrell
CHM | Chairman | 83 | 01/06/1989 |
Carol Burt
BRD | Director/Board Member | 68 | 01/11/2013 |
Karen Drexler
BRD | Director/Board Member | 66 | 17/11/2017 |
Harjit Gill
BRD | Director/Board Member | 61 | 15/11/2018 |
Jan De Witte
BRD | Director/Board Member | 61 | 16/05/2019 |
John Hernandez
BRD | Director/Board Member | 59 | 18/11/2021 |
Desney Tan
BRD | Director/Board Member | 50 | 18/11/2021 |
| Director/Board Member | 54 | 15/08/2024 |
Holdings: ResMed, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
NYXOAH SA 3.96% | 17,27,864 | 3.96% | 5 M $ |
Company details: ResMed, Inc.
Group companies: ResMed, Inc.
| Name | Category and Sector |
|---|---|
ResMed Pty Ltd.
 ResMed Pty Ltd. Medical SpecialtiesHealth Technology Designs, manufactures and markets devices for evaluation and treatment of sleep disorders |
Medical Specialties
|
ResMed Corp.
 ResMed Corp. Medical SpecialtiesHealth Technology Designs, manufactures and markets devices for evaluation and treatment of sleep disorders |
Medical Specialties
|
Other Advanced Medical Equipment & Technology
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.29% | -2.36% | -18.79% | -13.17% | 2.93TCr | |
| -2.20% | -5.73% | +8.25% | -16.30% | 16TCr | |
| -1.62% | -6.43% | -24.84% | +36.71% | 15TCr | |
| -1.60% | -5.40% | -15.21% | -28.66% | 11TCr | |
| -1.62% | -2.32% | -49.76% | -1.86% | 7.83TCr | |
| +0.05% | +1.78% | +5.85% | -8.48% | 4.69TCr | |
| -2.08% | -0.71% | -31.63% | -39.05% | 4.33TCr | |
| -1.20% | -7.30% | -6.37% | +20.46% | 3.23TCr | |
| -1.38% | -3.39% | -0.62% | -12.73% | 3.16TCr | |
| -0.54% | -6.00% | -29.84% | -48.26% | 2.85TCr | |
| Average | -1.25% | -4.24% | -16.29% | -11.13% | 7.17TCr | |
| Weighted average by Cap. | -1.54% | -4.89% | -14.96% | -5.86% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RMD Stock
- Company ResMed, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition